George Simeon — SEC Form 4 filings
SEC reporting owner CIK 1595117. 16 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-02-27 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 15 legs across 6 filings — 6,462,531 shares, $131,899,881 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 1,780 shares, $32,040 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: purchase of 960,983 shares @ $52.03 ($49,999,945) in CRISPR Therapeutics AG, filed 2025-07-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | Director | 5 | 3 legs · 989,812 sh · $51,499,918 | — | 6 |
| Zenas BioPharma, Inc. (ZBIO) | 10% owner | 2 | 5 legs · 2,361,609 sh · $40,399,983 | — | 6 |
| Nkarta, Inc. (NKTX) | Director | 4 | 2 legs · 2,000,000 sh · $20,000,000 | — | 3 |
| Odyssey Therapeutics, Inc. (ODTX) | 10% owner | 1 | 3 legs · 555,555 sh · $9,999,990 | 3 legs · 1,780 sh · $32,040 | 30 |
| Avalyn Pharma Inc. (AVLN) | 10% owner | 1 | 2 legs · 555,555 sh · $9,999,990 | — | 8 |
| Design Therapeutics, Inc. (DSGN) | Director, 10% owner | 3 | — | — | 3 |
Form 4 filings — George Simeon
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Odyssey Therapeutics, Inc. (ODTX) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 474,048 · Conversion (C): 139,366 · Conversion (C): 59,692 · Conversion (C): 61,762 · Conversion (C): 683,817 · Option exercise/expiry (X): 191,541 · +30 more | EDGAR |
| 2026-05-01 | 4 | Avalyn Pharma Inc. (AVLN) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 more | EDGAR |
| 2025-10-14 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Purchase (P): 63,158 @ $19 · Purchase (P): 63,157 @ $19 | EDGAR |
| 2025-07-17 | 4 | CRISPR Therapeutics AG (CRSP) | Purchase (P): 6,510 @ $52.03 · Purchase (P): 22,319 @ $52.03 · Purchase (P): 960,983 @ $52.03 | EDGAR |
| 2025-06-12 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 46,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 1,505,388 · Purchase (P): 441,176 @ $17 · Conversion (C): 501,796 · Purchase (P): 1,352,942 @ $17 · Conversion (C): 669,061 · Purchase (P): 441,176 @ $17 · +3 more | EDGAR |
| 2024-06-17 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Nkarta, Inc. (NKTX) | Purchase (P): 1,548,341 @ $10 · Purchase (P): 451,659 @ $10 | EDGAR |
| 2024-02-27 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 63,177 @ $71.50 · Grant/award (A): 216,578 @ $71.50 · Grant/award (A): 769,196 @ $71.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1595117 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →